Nestin expression in end-stage disease in dystrophin-deficient heart: Implications for regeneration from endogenous cardiac stem cells

Stem Cells Translational Medicine

Volumn 2, Issue 11, 2013, Pages 848-861

  Berry, Suzanne E ^a   Andruszkiewicz, Peter ^a   Chun, Ju Lan ^a   Hong, Jun ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cardiac; Muscle stem cells; Muscular dystrophy; Nestin; Sca 1; Tissue regeneration

Indexed keywords

ATAXIN 1; CD163 ANTIGEN; CD68 ANTIGEN; CONNEXIN 43; DESMIN; NESTIN; TRANSCRIPTION FACTOR; TROPONIN I; UTROPHIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL REGENERATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; HEART MUSCLE; IMMUNOCYTOCHEMISTRY; MACROPHAGE; MOUSE; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; STEM CELL; STEM CELL TRANSPLANTATION;

MURINAE; MUS;

EID: 84886549295     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0174     Document Type: Article

References (86)

1. Sejersen T, Lendahl U. Transient expression of the intermediate filament nestin during skeletal muscle development. J Cell Sci 1993; 106:1291-1300.
2. Kachinsky AM, Dominov JA, Miller JB. Intermediate filaments in cardiac myogenesis: Nestin in the developing mouse heart. J Histochem Cytochem 1995;43:843-847.
3. Cattaneo E, McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature 1990; 347:762-765.
4. Lendahl U, Zimmerman L, McKay R. CNS stem cells express a new class of intermediate filament protein. Cell 1990;60:585-595.
5. Wiese C, Rolletschek A, Kania G et al. Nestin expression: A property of multilineage progenitor cells? Cell Mol Life Sci 2004;61:2510-2522.
6. Sugiyama T, Nagasawa T. Bone marrow niches for hematopoietic stem cells and immune cells. Inflamm Allergy Drug Targets 2012; 11:201-206.
7. Wojakowski W, Ratajczak MZ, Tendera M. Mobilization of very small embryonic-like stem cells in acute coronary syndromes and stroke. Herz 2010;35:467-472.
8. Amoh Y, Li L, Katsuoka K et al. Multipotent nestin-expressing hair follicle stem cells. J Dermatol 2009;36:1-9.
9. Michalczyk K, Ziman M. Nestin structure and predicted function in cellular cytoskeletal organization. Histol Histopathol 2005;20:665-671.
10. Lendahl U. Transgenic analysis of central nervous system development and regeneration. Acta Anaesthesiol Scand Suppl 1997;110: 116-118.
11. Krum J, Rosenstein J. Transient coexpression of nestin, GFAP, and vascular endothelial growth factor in mature reactive astroglia following neural grafting or brain wounds. Exp Neurol 1999;160:348-360.
12. Namiki J, Tator C. Cell proliferation and nestin expression in the ependymal of the adult rat spinal cord after injury. J Neuropathol Exp Neurol 1999;58:489-498.
13. Vaittinen S, Lukka R, Sahlgren C et al. The expression of intermediate filament nestin as related to vimentin and desmin in regenerating skeletal muscle. J Neuropathol Exp Neurol 2001;60:588-597.
14. El-Helou V, Béguin PC, Assimakopoulos J et al. The rat heart contains a neural stem cell population; Role in sympathetic sprouting and angiogenesis. J Mol Cell Cardiol 2008;45:694-702.
15. Béguin P, El-Helou V, Assimakopoulos J et al. The phenotype and potential origin of nestin cardiac myocyte-like cells following infarction. J Appl Physiol 2009;107:1241-1248.
16. Mokrý J, Karbanová J, Filip S et al. Phenotypic and morphological characterization of in vitro oligodendrogliogenesis. Stem Cells Dev 2008;17:333-341.
17. Scobioala S, Klocke R, Kuhlmann M et al. Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes. FASEB J 2008; 22:1021-1031.
18. Tomita Y, Matsumura K, Wakamatsu Y et al. Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart. J Cell Biol 2005;170:1135-1146.
19. Béguin PC, El-Helou V, Gillis M et al. Nestin+ stem cells independently contribute to neural remodeling of the ischemic heart. J Cell Physiol 2011;226:1157-1165.
20. + cardiac progenitor cells for myocardial regeneration. PLoS One 2011;6:e25265.
21. Chun J, O'Brien R, Song MH et al. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for Duchenne muscular dystrophy. Stem Cells Translational Medicine 2013;2:68-80.
22. Morrison L. Dystrophinopathies. Handb Clin Neurol 2011;101:11-39.
23. Emery AE. Population frequencies of inherited neuromuscular diseases: A world survey. Neuromuscul Disord 1991;1:19-29.
24. Spurney CF, Guerron AD, Yu Q et al. Membrane sealant poloxamer P188 protects against Isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord 2011;11:20-30.
25. Eagle M, Bourke J, Bullock R et al. Managing Duchenne muscular dystrophy: The additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007;17:470-475.
26. Eagle M, Baudouin SV, Chandler C et al. Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926-929.
27. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990;26:271-277.
28. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy: 7th-9th June 2002, Naarden, the Netherlands. Neuromuscular Disord 2003;13:166-172.
29. Baxter P. Treatment of the heart in Duchenne muscular dystrophy. Dev Med Child Neurol 2006;48:163.
30. Romfh A, McNally EM. Cardiac assessment in Duchenne and Becker muscular dystrophies. Curr Heart Fail Rep 2010;7:212-218.
31. Duboc D, Meune C, Lerebours G et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005;45:855-857.
32. Ramaciotti C, Heistein LC, Coursey M et al. Left ventricular function and response to Enalapril in patients with Duchenne muscular dystrophy during the second decade of life. Am J Cardiol 2006;98:825-827.
33. Duboc D, Meune C, Pierre B et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602.
34. Rhodes J, Margossian R, Darras BT et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008; 29:343-351.
35. Kajimoto H, Ishigaki K, Okumura K et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006; 70:991-994.
36. Viollet L, Thrush PT, Flanigan KM et al. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012;110:98-102.
37. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 1999;137:895-902.
38. Jefferies JL, Eidem BW, Belmont JW et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005;112:2799-2804.
39. Ogata H, Ishikawa U, Ishikawa Y et al. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009;53: 72-78.
40. Biggar WD, Harris VA, Eliasoph L et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
41. Silversides CK, Webb GD, Harris et al. Effects of Deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003;91:769-772.
42. Markham LW, Spicer RL, Khoury PR et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 2005;26:768-771.
43. Markham LW, Kinnett K, Wong BL et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008;18: 365-370.
44. Houde S, Filiatrault M, Fournier A et al. Deflazacort use in Duchenne muscular dystrophy: An 8-year follow-up. Pediatr Neurol 2008; 38:200-206.
45. Koh GY, Soonpaa MH, Klug MG et al. Stable fetal cardiomyocyte grafts in the hearts of dystrophic mice and dogs. J Clin Invest 1995; 96:2034-2042.
46. Payne TR, Oshima H, Sakai R et al. Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cells. Gene Ther 2005;12:1264-1274.
47. Hagège AA, Marolleau JP, Vilquin JT et al. Skeletal myoblast transplantation in ischemic heart failure. Long-term follow-up of the first phase I cohort of patients. Circulation 2006; 114:I108-I113.
48. Menasché P. Stem cell therapy for heart failure: Are arrhythmias a real safety concern? Circulation 2009;119:2735-2740.
49. Jasmin G, Tautu C, Vanasse M et al. Impaired muscle differentiation in explant cultures of Duchenne muscular dystrophy. Lab Invest 1984;50:197-207.
50. Iannaccone ST, Nagy B, Samaha FJ. Decreased creatine kinase activity in cultured Duchenne dystrophic muscle cells. J Child Neurol 1987;2:17-21.
51. Delaporte C, Dehaupas M, Fardeau M. Comparison between the growth pattern of cell cultures from normal and Duchenne dystrophy muscle. J Neurol Sci 1984;64:149-160.
52. Webster C, Blau HM. Accelerated agerelated decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapy. Somat Cell Mol Genet 1990;16:557-565.
53. Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 1983;80: 4856-4860.
54. Cassano M, Berardi E, Crippa S et al. Alteration of cardiac progenitor cell potency in GRMD dogs. Cell Transplant 2012;21:19451967.
55. Decary S, Hamida CB, Mouly V et al. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord 2000;10:113-120.
56. Luz MA, Marques MJ, Santo NH. Impaired regeneration of dystrophin-deficient muscle fibers is caused by exhaustion of myogenic cells. Braz J Med Biol Res 2002;35:691-695.
57. Grady RM, Teng H, Nichol MC et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 1997;90:729-738.
58. Chun JL, O'Brien R, Berry SE. Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy. Neuromuscul Disord 2012;22:368-379.
59. Burkin DJ, Wallace GQ, Nicol KJ et al. Enhanced expression of the α7β1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 2001;152: 1207-1218.
60. Sjöberg G, Edström L, Lendahl U et al. Myofibers from Duchenne/Becker muscular dystrophy and myositis express the intermediate filament nestin. J Neuropathol Exp Neurol 1994;53:416-423.
61. Bridges LR. The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice. J Neurol Sci 1986;72:147-157.
62. Quinlan JG, Hahn HS, Wong BL et al. Evolution of the mdx mouse cardiomyopathy: Physiological and morphological findings. Neuromuscul Disord 2004;14:491-496.
63. Bostick B, Yue Y, Long C, Duan D. Prevention of dystrophindeficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 2008; 102:121-130.
64. Verhaart IEC, van Duijn RJM, den Adel B et al. Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. Neuromuscul Disord 2012;22: 418-426.
65. George-Weinstein M, Foster RF, Gerhart JV et al. In vitro and in vivo expression of α7 integrin and desmin define primary and secondary myogenic lineages. Dev Biol 1993;156: 209-229.
66. Schaart G, Viebahn C, Langmann W et al. Desmin and titin expression in early postimplantation mouse embryos. Development 1989;107:585-596.
67. Ya J, Markman MWM, Wagenaar GTM et al. Expression of the smooth-muscle proteins α-smooth-muscle actin and calponin, and of the intermediate filament protein desmin are parameters of cardiomyocyte maturation in the prenatal rat heart. Anat Rec 1997;249:495-505.
68. Loh SH, Chan WT, Gong Z et al. Characterization of a zebrafish (Danio rerio) desmin cDNA: An early molecular marker of myogenesis. Differentiation 2000;65:247-254.
69. Arnold L, Henry A, Pronod F et al. Inflammatory monocytes recruited after skeletal muscle injury switch into anti-inflammatory macrophages to support myogenesis. J Exp Med 2007;204:1057-1069.
70. Schaier M, Vorwalder S, Sommerer C et al. Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in nephrectomized rats. Am J Phsiol Renal Physiol 2009;297: F769-F780.
71. Chazaud B, Brigitte M, Yacoub-Youssef H et al. Dual and beneficial roles of macrophages during skeletal muscle regeneration. Exerc Sport Sci Rev 2009;37:18-22.
72. Villalta SA, Nguyen HX, Deng B et al. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009;18:482-496.
73. El-Helou V, Dupuis J, Proulx C. Resident nestin+ neural-like cells and fibers are detected in normal and damaged rat myocardium. Hypertension 2005;46:1219-1225.
74. Iida M, Heike T, Yoshimoto M et al. Identification of cardiac stem cells with Flk-1, CD31, and VE-cadherin expression during embryonic stem cell differentiation. FASEB J 2005;19:371-378.
75. Kattman SJ, Huber TL, Keller GM. Multipotent Flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell 2006;11:723-732.
76. Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003;100: 12313-12318.
77. Lardon J, Rooman I, Bouwens L. Nestin expression in pancreatic stellate cells and angiogenic endothelial cells. Histochem Cell Biol 2002;117:535-540.
78. van Amerongen MJ, Harmsen MC, van Rooijen N et al. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007;170:818-829.
79. Nahrendorf M, Swirski FK, Aikawa E et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204:3037-3047.
80. Odintsov B, Chun J, Mulligan J et al. 14.1 T whole body MRI for detection of mesoangioblast stem cells in a murine model of Duchenne muscular dystrophy. Magn Reson Med 2011; 66:1704-1714.
81. Moretti A, Caron L, Nakano A et al. Multipotent embryonic Isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006;127:1151-1165.
82. Matsuura K, Nagai T, Nishigaki N et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem 2004; 279:11384-11391.
83. Smart N, Bollini S, Dubé KN et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature 2011;474:640-644.
84. Laugwitz KL, Moretti A, Lam J et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 2005; 433:647-653.
85. Beltrami AP, Barluchhi L, Torella D. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-776.
86. Senyo SE, Steinhauser ML, Pizzimenti CL et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2013;493:433-436.